338 related articles for article (PubMed ID: 32274760)
1. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
2. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
3. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
[TBL] [Abstract][Full Text] [Related]
4. The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases.
Potapenko A; Davidson JM; Lee A; Laird AS
Biochem J; 2024 Mar; 481(6):461-480. PubMed ID: 38497605
[TBL] [Abstract][Full Text] [Related]
5. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
Paulino R; Nóbrega C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
[TBL] [Abstract][Full Text] [Related]
6. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
7. Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.
Watchon M; Yuan KC; Mackovski N; Svahn AJ; Cole NJ; Goldsbury C; Rinkwitz S; Becker TS; Nicholson GA; Laird AS
J Neurosci; 2017 Aug; 37(32):7782-7794. PubMed ID: 28687604
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiological interplay between
Pereira Sena P; Weber JJ; Watchon M; Robinson KJ; Wassouf Z; Hauser S; Helm J; Abeditashi M; Schmidt J; Hübener-Schmid J; Schöls L; Laird AS; Riess O; Schmidt T
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34785590
[TBL] [Abstract][Full Text] [Related]
9. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
10. KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.
Abeditashi M; Weber JJ; Pereira Sena P; Velic A; Kalimeri M; Incebacak Eltemur RD; Schmidt J; Hübener-Schmid J; Hauser S; Macek B; Riess O; Schmidt T
Cell Mol Life Sci; 2022 Jul; 79(8):401. PubMed ID: 35794401
[TBL] [Abstract][Full Text] [Related]
11. Protective roles of carbonic anhydrase 8 in Machado-Joseph Disease.
Hsieh M; Hsieh BY; Ma CY; Li YT; Liu CS; Lo CM
J Neurosci Res; 2019 Oct; 97(10):1278-1297. PubMed ID: 31157458
[TBL] [Abstract][Full Text] [Related]
12. The Neuropathology of Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.
Koeppen AH
Adv Exp Med Biol; 2018; 1049():233-241. PubMed ID: 29427106
[TBL] [Abstract][Full Text] [Related]
13. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
Raj K; Akundi RS
Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
[TBL] [Abstract][Full Text] [Related]
14. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
[TBL] [Abstract][Full Text] [Related]
15. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
16. Physiological and pathophysiological characteristics of ataxin-3 isoforms.
Weishäupl D; Schneider J; Peixoto Pinheiro B; Ruess C; Dold SM; von Zweydorf F; Gloeckner CJ; Schmidt J; Riess O; Schmidt T
J Biol Chem; 2019 Jan; 294(2):644-661. PubMed ID: 30455355
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry analyses of normal and polyglutamine expanded ataxin-3 reveal novel interaction partners involved in mitochondrial function.
Kristensen LV; Oppermann FS; Rauen MJ; Fog K; Schmidt T; Schmidt J; Harmuth T; Hartmann-Petersen R; Thirstrup K
Neurochem Int; 2018 Jan; 112():5-17. PubMed ID: 29111377
[TBL] [Abstract][Full Text] [Related]
18. Targeting the VCP-binding motif of ataxin-3 improves phenotypes in Drosophila models of Spinocerebellar Ataxia Type 3.
Johnson SL; Libohova K; Blount JR; Sujkowski AL; Prifti MV; Tsou WL; Todi SV
Neurobiol Dis; 2021 Dec; 160():105516. PubMed ID: 34563642
[TBL] [Abstract][Full Text] [Related]
19. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
20. Planning Future Clinical Trials for Machado-Joseph Disease.
Saute JAM; Jardim LB
Adv Exp Med Biol; 2018; 1049():321-348. PubMed ID: 29427112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
